Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Classification and diagnosis of Sjögren's syndrome

INTRODUCTION

Sjögren’s syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function. SS occurs in a primary form not associated with other diseases and in a secondary form that complicates other rheumatic conditions. The most common disease associated with secondary SS is rheumatoid arthritis.

In primary or secondary SS, decreased exocrine gland function leads to the “sicca complex,” a combination of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) [1,2]. In addition, a variety of other disease manifestations can occur in SS. The clinical manifestations of SS are divided into the exocrine gland features and the extraglandular disease features [3].

An effective classification system for SS must accommodate the range of clinical manifestations of this disorder. The ends of the clinical spectrum of SS are diverse:

  • At the severe end are patients with florid salivary gland enlargement, adenopathy, antibodies to the Ro/SSA and La/SSB antigens, cryoglobulinemia, hypocomplementemia, a propensity to develop non-Hodgkin lymphoma, and other extraglandular disease manifestations.
  • At the mild end are patients with moderate symptoms of dry eyes, dry mouth, a low titer of antinuclear antibody, and vague symptoms of fatigue, myalgias, and cognitive dysfunction. In many patients with mild disease, distinguishing SS patients from individuals with fibromyalgia or depression who have ocular and/or oral dryness caused or exacerbated by medications with anticholinergic side effects is a major challenge.
  • Another group of patients with extraglandular manifestations may be found to have antinuclear antibody and Ro/SSA antibody during evaluation, even though they lack dominant manifestations of dry eyes or dry mouth. These laboratory findings may be found during evaluation of neuropathies, nephropathies, hematologic abnormalities, or lymphoproliferative involvement of other organs with a pattern suggestive of SS or of systemic lupus erythematosus in the extraglandular organs.

This topic will review the classification, diagnosis, and epidemiology of SS. The clinical manifestations, pathogenesis, treatment, and prognosis of this disorder are discussed separately. (See "Clinical manifestations of Sjögren's syndrome: Exocrine gland disease" and "Clinical manifestations of Sjögren's syndrome: Extraglandular disease" and "Pathogenesis of Sjögren's syndrome" and "Treatment of dry eyes in Sjögren's syndrome" and "Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren's syndrome" and "Treatment of systemic and extraglandular manifestations of Sjögren’s syndrome".)

                                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Dec 19, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347.
  2. Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999; 58:423.
  3. Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study. J Intern Med 1996; 239:475.
  4. Mikulicz JH. Uber eine eigenartige symmetrische Erkrankung der Tranen- und Mundspeicheldrusen. In: Beitr. Chir. Fortschr, Billroth GT (Ed), Stuttgart, 1892. p.610.
  5. Ihrler S, Harrison JD. Mikulicz's disease and Mikulicz's syndrome: analysis of the original case report of 1892 in the light of current knowledge identifies a MALT lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:334.
  6. Sjögren H. Zur Kenntnis der Keratoconjunctivitis sicca. Acta Ophthalomol 1933; 11(suppl II):1.
  7. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900.
  8. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001; 76:593.
  9. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998; 37:1069.
  10. Jacobsson LT, Axell TE, Hansen BU, et al. Dry eyes or mouth--an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome. J Autoimmun 1989; 2:521.
  11. Drosos AA, Andonopoulos AP, Costopoulos JS, et al. Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol 1988; 27:123.
  12. Sánchez-Guerrero J, Pérez-Dosal MR, Cárdenas-Velázquez F, et al. Prevalence of Sjögren's syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology (Oxford) 2005; 44:235.
  13. Liew MS, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol 2012; 96:1498.
  14. Strickland RW, Tesar JT, Berne BH, et al. The frequency of sicca syndrome in an elderly female population. J Rheumatol 1987; 14:766.
  15. Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999; 159:1359.
  16. Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. Salisbury Eye Evaluation. J Rheumatol 1998; 25:486.
  17. Kang HI, Fei HM, Saito I, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjögren's syndrome. J Immunol 1993; 150:3615.
  18. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36:340.
  19. Afonso AA, Monroy D, Stern ME, et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999; 106:803.
  20. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998; 17:565.
  21. van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969; 82:10.
  22. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004; 164:1275.
  23. de Paiva CS, Pflugfelder SC. Tear clearance implications for ocular surface health. Exp Eye Res 2004; 78:395.
  24. Aung W, Yamada I, Umehara I, et al. Sjögren's syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 2000; 41:257.
  25. Hermann GA, Vivino FB, Goin JE. Scintigraphic features of chronic sialadenitis and Sjögren's syndrome: a comparison. Nucl Med Commun 1999; 20:1123.
  26. Kalk WW, Vissink A, Spijkervet FK, et al. Morbidity from parotid sialography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:572.
  27. Daniels TE, Benn DK. Is sialography effective in diagnosing the salivary component of Sjögren's syndrome? Adv Dent Res 1996; 10:25.
  28. Hu S, Wang J, Meijer J, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007; 56:3588.
  29. Giusti L, Baldini C, Bazzichi L, et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. Proteomics 2007; 7:1634.
  30. Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180:5130.
  31. Haldorsen K, Moen K, Jacobsen H, et al. Exocrine function in primary Sjögren syndrome: natural course and prognostic factors. Ann Rheum Dis 2008; 67:949.
  32. Porola P, Virkki L, Przybyla BD, et al. Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren's syndrome. J Rheumatol 2008; 35:2229.
  33. Laine M, Porola P, Udby L, et al. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjögren's syndrome. Arthritis Rheum 2007; 56:2575.
  34. Peluso G, De Santis M, Inzitari R, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum 2007; 56:2216.
  35. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 1985; 28:1128.
  36. Lee M, Rutka JA, Slomovic AR, et al. Establishing guidelines for the role of minor salivary gland biopsy in clinical practice for Sjögren's syndrome. J Rheumatol 1998; 25:247.
  37. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18:571.
  38. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974; 37:217.
  39. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheum 1994; 37:869.
  40. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 2002; 29:938.
  41. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 2002; 47:520.
  42. Morbini P, Manzo A, Caporali R, et al. Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Res Ther 2005; 7:R343.
  43. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984; 27:147.
  44. Brennan MT, Sankar V, Leakan RA, et al. Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients. Arthritis Rheum 2002; 47:189.
  45. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33:167.
  46. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40:1601.
  47. Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999; 42:455.
  48. Stone JH, Caruso PA, Deshpande V. Case records of the Massachusetts General Hospital. Case 24-2009. A 26-year-old woman with painful swelling of the neck. N Engl J Med 2009; 361:511.
  49. Chan EK, Tan EM, Ward DC, Matera AG. Human 60-kDa SS-A/Ro ribonucleoprotein autoantigen gene (SSA2) localized to 1q31 by fluorescence in situ hybridization. Genomics 1994; 23:298.
  50. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93.
  51. Ben-Chetrit E, Chan EK, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 1988; 167:1560.
  52. Arnett FC. Histocompatibility typing in the rheumatic diseases. Diagnostic and prognostic implications. Rheum Dis Clin North Am 1994; 20:371.
  53. Harley JB, Sestak AL, Willis LG, et al. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 1989; 32:826.
  54. Jungehülsing M, Fischbach R, Schröder U, et al. Magnetic resonance sialography. Otolaryngol Head Neck Surg 1999; 121:488.
  55. Tonami H, Ogawa Y, Matoba M, et al. MR sialography in patients with Sjögren syndrome. AJNR Am J Neuroradiol 1998; 19:1199.
  56. Heverhagen JT, Kalinowski M, Rehberg E, et al. Prospective comparison of magnetic resonance sialography and digital subtraction sialography. J Magn Reson Imaging 2000; 11:518.
  57. Eracleous E, Kallis S, Tziakouri C, et al. Sonography, CT, CT sialography, MRI and MRI sialography in investigation of the facial nerve and the differentiation between deep and superficial parotid lesions. Neuroradiology 1997; 39:506.
  58. Niemelä RK, Takalo R, Pääkkö E, et al. Ultrasonography of salivary glands in primary Sjogren's syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. Rheumatology (Oxford) 2004; 43:875.
  59. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554.
  60. Vitali C. Classification criteria for Sjögren's syndrome. Ann Rheum Dis 2003; 62:94.
  61. Fox RI. Sjögren's syndrome. Controversies and progress. Clin Lab Med 1997; 17:431.
  62. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994; 53:637.
  63. Vitali C, Bombardieri S. The European classification criteria for Sjögren's syndrome (SS): proposal for modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROCS) curve of the criteria performance. J Rheum 1997; 24:S18.
  64. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005; 32:143.
  65. Bowman SJ. Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002; 116:23.
  66. Bowman SJ, Booth DA, Platts RG, et al. Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. J Rheumatol 2003; 30:1259.
  67. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475.
  68. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79:47.
  69. Theander E, Jacobsson LT. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 2008; 34:935.
  70. Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006; 47:3293.
  71. Tiffany JM. The viscosity of human tears. Int Ophthalmol 1991; 15:371.
  72. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006; 176:3950.
  73. Begley CG, Himebaugh N, Renner D, et al. Tear breakup dynamics: a technique for quantifying tear film instability. Optom Vis Sci 2006; 83:15.
  74. Nakamori K, Odawara M, Nakajima T, et al. Blinking is controlled primarily by ocular surface conditions. Am J Ophthalmol 1997; 124:24.
  75. Peshori KR, Schicatano EJ, Gopalaswamy R, et al. Aging of the trigeminal blink system. Exp Brain Res 2001; 136:351.
  76. Wolkoff P, Nøjgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air 2006; 16:258.
  77. Sheedy JE, Gowrisankaran S, Hayes JR. Blink rate decreases with eyelid squint. Optom Vis Sci 2005; 82:905.
  78. Erdem U, Ozdegirmenci O, Sobaci E, et al. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas 2007; 56:257.
  79. Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol 2006; 22:501.
  80. Hensher R, Bowerman J. Actinomycosis of the parotid gland. Br J Oral Maxillofac Surg 1985; 23:128.
  81. Janmeja AK, Das SK, Kochhar S, Handa U. Tuberculosis of the parotid gland. Indian J Chest Dis Allied Sci 2003; 45:67.
  82. Ramos-Casals M, Brito-Zerón P, García-Carrasco M, Font J. Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore) 2004; 83:85.
  83. Kim D, Uy C, Mandel L. Sialosis of unknown origin. N Y State Dent J 1998; 64:38.
  84. Buchanan JA, Fortune F. Bilateral parotid enlargement as a presenting feature of bulimia nervosa in a post-adolescent male. Postgrad Med J 1994; 70:27.
  85. Vavrina J, Müller W, Gebbers JO. Enlargement of salivary glands in bulimia. J Laryngol Otol 1994; 108:516.
  86. Manetti L, Bogazzi F, Brogioni S, et al. Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 2002; 57:97.
  87. Thomson JA, McCrossan J, Mason DK. Salivary gland enlargement in acromegaly. Clin Endocrinol (Oxf) 1974; 3:1.